Fluzopalil in Combination With Anlotinib for Extensive Small-cell Lung Cancer

Summary

This is a the researchers launched a multicenter, prospective, single arm phase II clinical study, the group always had at least two cycle line standard platinum-based treatment and curative effect for SD, at least 6 months during or after the treatment of disease progression broad stage small cell lung cancer patients, evaluating the efficacy and safety of fluzopalil combination With anlotinib. Fifty patients are expected to be enrolled in this study.

Timeline

Start

2021-06

Primary completion

2022-06

Completion

2023-06

Publications

• Li D, Huang Z, Zhong J, Lin L, Zhang G, Zhuang W, Liu Z. Efficacy and safety of fluzoparib combined with anlotinib in extensive stage small cell lung cancer after first-line platinum-based chemotherapy: a multi-center, single-arm prospective phase II clinical study (STAMP study). BMC Cancer. 2023 Aug 14;23(1):753. doi: 10.1186/s12885-023-11230-5.

Drugs

Indications